Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Plasma neurofilament light chain predicts Alzheimer’s pathology and progression of cognitive decline in patients with subjective cognitive decline and mild cognitive impairment: a longitudinal study
Aging, Dementia, Cognitive, and Behavioral Neurology
P10 - Poster Session 10 (8:00 AM-9:00 AM)
NfL is a non-specific marker of neurodegeneration. In a previous cross-sectional study, we demonstrated that plasmatic NfL levels change as a function of Aβ status.
To evaluate the accuracy of plasma neurofilament light chain in predicting Alzheimer’s disease biomarker status and progression of cognitive decline in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI).
119 patients (35 SCD, 59 MCI, and 25 AD) underwent plasma NfL and CSF biomarker measurement at baseline. They were rated according to the A/T(N) system (Jack et al., 2016) and classified as carriers of the AD pathology (AP+) when A+ was associated with either T+ or N+, or non-carriers (AP–) when they were rated as A– (regardless of T and N classification), or as A+/T-/N-. 38 patients had plasma NfL measurement after two years from baseline collection.
NfL levels were significantly different between SCD, MCI and AD. NfLs were higher in AP+ as compared to AP– (p<0.001), both in SCD and MCI groups. We identified a cut-off of 20.40 pg/mL to distinguish between AP– and AP+ with a high accuracy (AUC = 0.84) and a very high positive predictive value (91.67%). During the follow-up, NfLs levels increased by 0.63 and 1.13 pg/mL per year in AP– and AP+ patients respectively. Interestingly, mean NfL level in AP– patients never significantly exceed 20 pg/mL. Moreover, five SCDs (14.28%) progressed to MCI and eleven MCIs (18.64%) progressed to AD. NfL showed a very high negative predictive value in estimating the odds of progression to MCI (95.83%) and to AD (88.89%) by applying 20.40 pg/mL as cut-off value.
NfL is not specific for AD. Nevertheless, if applied on on a selected population  (patients with memory complaint or impairment without other possible causes), NfL is a reliable, non-invasive tool to detect Alzheimer’s pathology at the earliest stages.
Salvatore Mazzeo (University of Florence)
Mr. Mazzeo has nothing to disclose.
Silvia Bagnoli, PhD (LABORATORIO DI N UROGENETICA presso cubo3 pad27/b) Dr. Bagnoli has nothing to disclose.
Sonia Padiglioni Sonia Padiglioni has nothing to disclose.
Giulia Giacomucci Ms. Giacomucci has nothing to disclose.
Assunta Ingannato (University of Florence) Dr. Ingannato has nothing to disclose.
Filippo Emiliani, MD Dr. Emiliani has nothing to disclose.
Valentina Moschini, Neuropsychologist (Azienda Ospedaliero Universitaria Careggi) Miss Moschini has nothing to disclose.
Giulia Galdo, MD Dr. Galdo has nothing to disclose.
Carmen Morinelli Miss Morinelli has nothing to disclose.
Sandro Sorbi Sandro Sorbi has nothing to disclose.
Benedetta Nacmias Benedetta Nacmias has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier.
Valentina Bessi Valentina Bessi has nothing to disclose.